Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Therapeutic Devices
dreamed-diabetes.com

See what CB Insights has to offer

Founded Year

2014

Stage

Seed - II | Alive

Total Raised

$8.7M

Last Raised

$3.3M | 6 yrs ago

About DreaMed Diabetes

DreaMed Diabetes develops health solutions and decision support tools using algorithms for the optimization of intensive insulin therapy for the benefit of people with Type 1 and Type 2 diabetes. The company's first product, GlucoSitter, was developed for closed-loop insulin therapy and was licensed to Medtronic. The company's latest product, Advisor, its decision support technology platform for determining the optimal patient-specific insulin treatment plans leading to balanced glucose levels in people with diabetes. The system uses event-driven machine learning and logic technology in order to process multiple personalized parameters, such as insulin delivery data, glucose readings, meal data and more into an informed and optimized insulin dosing treatment plan.

DreaMed Diabetes Headquarter Location

3 Shimshon St

Petah Tikva, 4952701,

Israel

Latest DreaMed Diabetes News

Pediatric Endocrinology Clinic At University Of Florida Expands Implementation Of DreaMed Technology

Nov 4, 2021

Share The clinic will begin using the Advisor Pro Decision-Support System for Type 2 Diabetes, which has recently received FDA clearance, enhancing the clinic’s offering to health care practitioners and patients Related Posts DreaMed Diabetes AI LTD. developer of the AI-powered Advisor Pro Clinical Decision Support System and expert-care platform for diabetes, announced the expansion of its commercial relationship with the Pediatric Endocrinology Clinic at the University of Florida in Gainesville, Fla. The clinic will begin using the Advisor Pro Decision-Support System for people with Type 2 and Type 1 diabetes, enhancing its offering to health care practitioners and patients. Advisor Pro by DreaMed is an Al Clinical Decision Support System for diabetes, providing remote insulin management with data analysis and disease management tools. The solution will be deployed at the hospital together with existing diabetes management protocols in an effort to provide patients a more personalized, precise, and effective diabetes treatment. In the United States alone, 34.2 million people—just over 1 in 10—have diabetes. When it comes to youth diabetes, according to American Diabetes Association, about 210,000 Americans under age 20 are estimated to have been diagnosed with diabetes. Advisor Pro is the first decision support system to receive FDA clearances for Type 1 and Type 2 diabetes treatments – for pediatrics and adults. The solution leverages AI to optimize insulin administration and assist healthcare providers in caring for diabetes patients who use insulin pumps or injections and monitor their glucose. This coveted achievement came on the heels of a prestigue recognition by Nature Medicine. In September 2020, the magazine published a significant international study where the Pediatric Endocrinology Clinic at the University of Florida was a participant. The multicenter, multinational, six-month study reported equal improvement in clinical outcomes when using the AI-backed DreaMed Advisor® compared with physician-guided recommendations. Following the study, in late 2020 and 2021, the clinic piloted DreaMed Advisor Pro®. After a successful trial, the clinic decided to implement the all-in-one DreaMed solution clinic-wide, adding the recently cleared upgraded DreaMed Advisor Platform to its offering and eliminating the need for multiple platforms. In addition to supporting patients on their health journey, the agreement between the clinic and the Company will allow the clinic to deploy features that can help streamline and optimize reimbursements from healthcare plans, to support patients administratively and financially. “Digital medicine applications can vastly improve the access of patients to healthcare. Remote medicine is part of the future of healthcare, and clinics need to deploy remote care solutions to deliver better care to their patients,” says Dr. Haller from the Pediatric Endocrinology Clinic at the University of Florida. Eran Atlas , DreaMed CEO, comments: “The future is un-siloed: digital medicine enhances physician-led medicine to bring better health, better life experience, and better life expectancy to patients. We are very pleased to see a U.S. leading Pediatric Endocrinology Clinic at University of Florida expand its relationship with DreaMed to make an even bigger difference in people’s lives. We will be able to use this deal for expansion into its adult Endo and PCP departments as well as leverage the transaction and its model nationally with other potential customers”.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing DreaMed Diabetes

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

DreaMed Diabetes is included in 4 Expert Collections, including Digital Health.

D

Digital Health

12,660 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

A

Artificial Intelligence

8,323 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

M

Medical Devices

11,401 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

D

Diabetes

1,750 items

DreaMed Diabetes Patents

DreaMed Diabetes has filed 4 patents.

The 3 most popular patent topics include:

  • Diabetes
  • Insulin therapies
  • Blood tests
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/21/2015

11/29/2016

Diabetes, Insulin therapies, Blood tests, Implants (medicine), ARM architecture

Grant

Application Date

1/21/2015

Grant Date

11/29/2016

Title

Related Topics

Diabetes, Insulin therapies, Blood tests, Implants (medicine), ARM architecture

Status

Grant

DreaMed Diabetes Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

DreaMed Diabetes Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.